Davis et al. (2020) [40] showed that the clinical outcome of the CYP2C19 heterozygous genotype was better than that of the CYP2C19 homozygous genotype in patients with acute myocardial infarction, and the results in this work were similar to those of the CYP2C19 heterozygous genotype. The gene discussed is CYP2C19; the disease is acute myocardial infarction.